therapy for antidepressant medication, which can have neuropsychological deficits of its own. In polydrug trials, side effects can be potentiated due to interactions between drugs. 11 Data on standard neuropsychological tests have revealed within-group improvements 3, 10, [12] [13] [14] [15] [16] or improvements in means by time × treatment interaction 12, 17 on several cognitive measures in the majority of antidepressant rTMS trials (Table 1 ). In the present study, some patients received rTMS to both the right and the left prefrontal cortex at different stimulation frequencies. With the exception of 2 reports, 18, 19 little is known about the safety of bilateral rTMS application. The aggressive stimulation parameters used, in order to enhance antidepressant outcome, have never been carefully assessed before and could have been a source of cognitive impairment. For example, Loo et al., 19 using a simultaneous bilateral hfrTMS, described a significant initial weak deleterious effect on problem-solving skills in patients during a 3-week trial. In consideration of the imponderability of cognitive outcome, we sought to monitor neurocognitive aspects in patients who underwent active treatment designed to enhance antidepressant outcome, in comparison with shamstimulated patients.
METHOD Patients
The study was designed as a single-center, prospective, double-blind, sham-controlled trial. Forty-one patients with a diagnosis of a depressive episode in the course of major depression or bipolar I disorder according to DSM-IV criteria were consecutively chosen from a sample of inpatients from a psychiatric ward at the University Hospital Innsbruck, Innsbruck, Austria. The ethics committee of the University of Innsbruck approved the study design. At admission to the ward, a washout of antidepressant medication was performed for a duration dependent on the 5-fold half-life of the drug that the patient was taking. After a complete description of the study to the subjects, written informed consent was obtained prior to participation. All patients received rTMS during a 2-week time period (2 × 5 sessions with a 2-day break). In order to speed up the expected antidepressant effect, an "add-on" study paradigm was chosen, and antidepressant medication was commenced on the first day of stimulation and maintained throughout the stimulation period. Dosage remained constant during the trial. Data were collected from November 1999 to August 2002.
The 41 patients were randomly assigned to 1 of 3 groups: A1, A2, and C (A1 = active unilateral stimulation, A2 = active bilateral stimulation, and C = control [sham group]). In addition, all patients, irrespective of randomization, received an antidepressant drug the first day of rTMS. Three patients, 1 from each group, terminated the study prematurely. One patient dropped out because she could not tolerate the uncomfortable sensation inherent to hf-rTMS, 1 patient (group A2) was excluded because she developed a manic symptomatology, and a third patient was transferred to another hospital closer to his home 1 day before terminating the stimulation protocol.
Group A1. Patients (N = 12) received hf-rTMS applied to the left DLPFC (20 Hz, 100% motor threshold (MT), 10 trains of 10 seconds' duration with a 90-second intertrain interval, resulting in a total of 2000 stimuli per session for 2 × 5 days). After a 5-minute break, a lowfrequency sham stimulation was applied over the right DLPFC.
Group A2. Patients (N = 13) underwent active hfrTMS of the left DLPFC as described for Group A1 followed by active lf-rTMS over the right DLPFC (1 Hz, 120% MT, for 10 minutes, resulting in a total of 2600 stimuli per session for 2 × 5 days).
Group C. Patients (N = 13) who served as a control group received bilateral sham stimulation, hf-rTMS to the left DLPFC, followed by lf-rTMS to the right DLPFC.
Repetitive Transcranial Magnetic Stimulation Procedure
Magnetic stimulator. Stimulation was performed with a Magstim 200 Rapid Stimulator (Magstim Company Limited, Spring Gardens, Whitland, U.K.).
Coil placement and orientation. Active stimulation was performed with a figure 8-shaped focal coil centered to the left and right DLPFC as defined by the individual's magnetic resonance imaging. Identical to the handling of the active coil, the sham coil was placed onto the patient's head; the only difference was that this coil was disconnected from the stimulator. At the same time, a second active coil was held 10 cm behind the patient's head. This coil produced the acoustic artifact as required by randomization group. This kind of sham stimulation was chosen in order to avoid a sham paradigm previously described to be somewhat active.
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Stimulation. Surface electromyographic electrodes were attached bilaterally over the first dorsal interosseous muscle, and the patient's individual MT at rest was determined bilaterally. The doctor-patient interaction was standardized and was consistent for all treatment groups.
Safety. The stimulation parameters used must be considered aggressive, as they are out of range of commonly used safety recommendations. 21 Patients were informed of this fact, and specific precautions were implemented. Surface electrodes remained attached during stimulation in order to enable early recognition of possible intracerebral stimulus spreading. Nonblinded psychiatrists performed stimulation, and neurophysiological monitoring was performed by a clinical neurophysiologist or by a psychiatrist trained in the particular aspects of detecting signs of seizure activity. F o r p e r s o n a l a n d r e s e a r c h u s e o n l y
Ratings for Depression
Patients were evaluated using the 21-item Hamilton Rating Scale for Depression (HAM-D-21) 22 and the Beck Depression Inventory (BDI) 23 at baseline (day 0) and following stimulation (day 14). Between day 0 and day 14, patients were evaluated at days 1, 3, 5, 7, and 10. Blinded trained psychiatrists who underwent biweekly interrater training performed all ratings.
Neuropsychological Measures
Neuropsychological assessment was done before (baseline, day 0) and following (day 14) rTMS using standardized psychometric testing procedures focusing on motor skills, attention, executive functions, learning, and memory. Verbal memory functions were evaluated with the Muenchner Verbaler Gedaechtnistest (MVG), 24 a German equivalent of the California Verbal Learning Test. 25 This test measures learning, short-term and long-term verbal memory, and word recognition. In order to minimize practice effects, a paired alternate test form of the MVG was used. To test psychomotor speed, attention, and cognitive flexibility, the Trail Making Test (TMT) 26 was administered. Selective attention, set shifting, and suppression of distraction were evaluated using the ColorWord Interference Test (Stroop Test). 27 The Stroop Test is suitable for evaluating special aspects of selective attention, namely susceptibility to interference, and examines conflicts between automated and controlled information processing. 28, 29 The verbal fluency test was adapted from the Controlled Oral Word Association Test. 30 Letter fluency (F, A, S) and category fluency (supermarket, animals, vegetables) were each tested in 60-second trials. The mean number of words produced in each of the 2 trials was the outcome of interest.
Statistical Analysis
The 3 treatment groups (A1, A2, C) were compared with respect to patient characteristics and baseline neuropsychological performance and depression scores (HAM-D-21 and BDI) by 1-way analysis of variance (ANOVA) or χ 2 test, depending on the variable type. The 2 actively treated groups (A1, A2) were then compared regarding neuropsychological performance, both at baseline and day 14, using 1-way ANOVA and, due to a lack of group differences, were pooled for all further parts of the analysis.
Changes in neuropsychological parameters (day 0 vs. day 14) were analyzed both within and between groups (active treatment vs. sham), using paired t tests for the showed marked non-normality and were therefore subjected to an appropriate normalizing transformation before performing the ANOVAs. The relationship between neuropsychological performance measures and depression, both at fixed time points and in the course of time, was analyzed using Spearman correlation coefficients (Pearson correlation coefficients would have yielded very similar results). Data on dropouts were analyzed using the last observation carried forward method. Observations were carried forward for a maximum time span of 4 days. All significance levels reported are 2-tailed without adjustment for multiple testing. However, for scrutinizing group differences, Bonferroni-corrected significance levels were calculated additionally for group-by-time interactions.
Power Analysis
The sample size of 25 subjects receiving active treatment (groups A1 + A2) and 13 control subjects (group C) was large enough to detect, under standard assumptions (80% power, significance level of α = .05), betweengroup differences exceeding an effect size of 1.01 and within-group differences (day 0 vs. day 14) beyond an effect size of 0.58 for the active treatment group and beyond an effect size of 0.88 for the sham group. The sample size, which is larger than those in most other rTMS studies, 17 is therefore sufficiently high to reveal moderate withingroup differences, especially in the active treatment group, but allows only for the detection of marked between-group differences.
RESULTS
The 3 groups did not differ significantly with regard to age, gender, and disease characteristics ( Table 2 ). There were no significant differences between the 3 groups (A1, A2, and C) or between the pooled treatment groups (A1 + A2) and the sham group in terms of HAM-D-21 and BDI scores at baseline (day 0).
Safety
In general, given the seizure-induction potential of the used paradigm, treatment conditions were well tolerated F o r p e r s o n a l a n d r e s e a r c h u s e o n l y overall. With the exception of 2 patients complaining of headache (group A1 and C) and 1 patient exerting a manic symptomatology (group A2), there were no adverse events, including seizures.
Cognitive Outcomes
Unilaterally stimulated group (A1) compared with the bilaterally stimulated group (A2). Our analysis revealed no difference in any of the neuropsychological measures between the 2 active treatment groups. Thus, data from the 2 actively treated groups were pooled in order to increase statistical power (Table 3) .
Changes within the active treatment groups (A1 + A2). After 2 weeks of treatment, a statistically significant improvement in 2 neuropsychological variables, namely Stroop 2 (p = .008) and Stroop 3 (p = .001), was seen in the actively treated group (A1 + A2) but not in the control group. In addition, a significant improvement could be observed in TMT A and B, which reflects an amelioration of psychomotor speed and set shifting ability. A trend toward better performance was also found in verbal fluency (letter). No other significant changes in neuropsychological performance were observed within the treated groups, neither in terms of an increase nor a decrease in performance (Table 3) .
Active treatment groups (A1 + A2) compared with the sham-stimulated group (C). When comparing the actively treated patients with the sham-stimulated controls, only 1 of the neuropsychological measures showed a statistically significant group-by-time interaction, namely MVG encoding trial 5 (p = .028). Data indicate that actively treated patients showed a significantly more favorable time course in this parameter than sham-stimulated patients. This result remained significant after adjustment for changes in depression scores (HAM-D-21, BDI) by analysis of covariance (p = .037). However, there was no other significant group × time interaction effect, and the statistical significance in the MVG measure is not retained after a Bonferroni correction for multiple testing.
Depression Outcomes
Both HAM-D-21 and BDI scores decreased significantly from baseline to day 14 in the 2 active groups as well as in the sham group (Table 2) . However, there was no significant difference between the active treatment groups (N = 25) and the sham-stimulated group (N = 13) in terms of a decrease in HAM-D-21 and BDI scores over time (days 0-14). 31 
Correlation Between Measures of Cognition and Depression
At baseline, only a single significant correlation between a cognitive measure and depression was found in the total sample, namely a positive correlation between BDI and Stroop 3 (Spearman correlation r = 0.34, p = .050). As this result does not withstand a Bonferroni correction for multiple testing, the possibility of a chance finding cannot be ruled out. Improvement in BDI total score (days 0 to 14) correlated significantly with improvements in Stroop 2 and 3 in the same period of time, both in the total sample (r = 0.47, p = .012 and r = 0.40, p = .037, respectively) and in the pooled active treatment groups A1 and A2 (r = 0.61, p = .012 and r = 0.52, p = .041, respectively). Moreover, in the latter group, a significant association between improvement in HAM-D-21 scores and improved memory performance was observed (for MVG encoding trial 1 as well as MVG encoding trial 5 and MVG encoding trials 1-5: r > 0.5, p ≤ .046).
DISCUSSION
We analyzed neurocognitive data from 38 patients with depression who underwent a neuropsychological test battery at baseline and following a 2-week unilateral and F o r p e r s o n a l a n d r e s e a r c h u s e o n l y bilateral rTMS add-on trial using aggressive stimulation parameters. The main finding in our study was that patients showed no deterioration in cognitive functions after 2 weeks of unilateral and bilateral rTMS compared with sham stimulation. As revealed in Table 3 , the short-term course (day 0 vs. day 14) of all cognitive parameters was slightly better for group A1 + A2 than for group C, surely supporting the lack of detrimental cognitive impact of the intervention. Our data on the within-group improvement of TMT A and B scores parallel previous data by Moser et al., 17 who reported a significant time-by-treatment interaction in the TMT B in comparison with sham, and also parallel data of Hoeppner et al., 32 who reported a significant improvement of motor retardation after active treatment over the left DLPFC (20 Hz) or the right DLPFC (1 Hz).
Furthermore, patients in the active rTMS treatment groups showed a more favorable time course for encoding in the verbal memory test compared with the shamstimulated patients ( Table 3 ). Given that controlling for depressive symptomatology did not lead to changes in our results, one might consider this finding to be independent of the alleviation of depressive symptoms.
The finding of no deleterious effects on cognition in the unilateral left DLPFC-stimulated sample (group A1) are consistent with the findings of other studies that also reported a lack of deleterious neurocognitive impact of rTMS over the left DLPFC in depressive patients. 3, 10, [12] [13] [14] 17, 19, 33 In addition, we were able to show that a bilateral stimulation as used in the present study (group A2) does not exert additional cognitive side effects in comparison with unilateral stimulation (group A1) or sham stimulation (group C). A comparable outcome was seen in a bilateral rTMS trial by Cohen et al. 18 using a similar paradigm as that of group A2 but employing a noncontrolled study design on a small number of patients (N = 10) and limiting neuropsychological assessment to a brief global screening of cognitive functions, namely the Mini-Mental State Examination. Our study used an extensive neuropsychological test battery, enrolled a larger cohort of patients, and applied a higher number of stimuli to the left DLPFC (20,000 vs. 6000) (hf-rTMS) and to the right DLPFC (32,000 vs. 1200) (lf-rTMS), thus providing novel safety data on bilateral rTMS.
Our data are also in line with Loo et al., 19 who did not find noxious rTMS effects on cognition in their simultaneous bilateral stimulation trial with 9 actively treated and 10 sham-stimulated participants. In addition to sample size, differences from our study design include the stimulation frequency (15 Hz bilateral vs. 20 Hz unilateral left and 1 Hz unilateral right), duration of stimulation (3 weeks vs. 2 weeks), and application mode (simultaneous bilateral stimulation vs. subsequent bilateral stimulation). The small sample of recruited patients in the active treatment group (N = 9) and the sham group (N = 10) in the study by Loo et al. 19 might have been a limitation to their findings. The choice of these parameters was aimed at increasing the antidepressant efficacy of rTMS. However, our trial failed to show a significant advantage of these rTMS parameters over sham stimulation in an add-on design. Testing of such bilateral rTMS parameters as mono- F o r p e r s o n a l a n d r e s e a r c h u s e o n l y therapy in comparison with antidepressant drug treatment might be desirable. Our findings support the safety of such an approach. In regard to the question of an add-on treatment potentially having more adverse effects than a single treatment alone, we found that, although not more effective in terms of antidepressant outcome, add-on rTMS (A1 + A2) had no more cognitive side effects than administration of an antidepressant with sham stimulation (C). To the best of our knowledge, our chosen aggressive stimulation parameters have never been used in an antidepressant trial. Although out of range of the usual parameters, 21 they seem to be safe not only in terms of a lack of seizures, but also in terms of a lack of cognitive deterioration in the aftermath of stimulation. Low incidence of headache was seen throughout the studied patients. This translates to an incidence of headache of less than 5%, including the subject in group C receiving sham stimulation. This incidence is actually lower than the incidence reported in current safety assessments of rTMS. 21, 34 As 1 patient in group A2 exerted symptoms of mania, it might be that the bilateral stimulation paradigm has inherent potential of inducing such symptoms. Alternatively, the add-on setting or the combination of both factors is to blame for this adverse event.
Several limitations to our data need to be addressed. First, despite the fact that the assessed number of actively treated patients (Table 3) is the largest ever reported, we cannot rule out that a larger sample may reveal differing effects in neuropsychological functioning after rTMS stimulation. The fact that we were not able to show a group difference in antidepressant outcome might be due to the difficult task of showing differences between 2 antidepressive biological intervention strategies. However, our results suggest that rTMS is more likely to increase than decrease neuropsychological functioning.
A second aspect addresses the add-on treatment with antidepressants, which in the present study was done on a naturalistic basis. More than half of patients in all groups received citalopram: 60% in the active groups and 54% in the sham group. Future studies using a controlled uniform medication treatment are needed to exclude the possibility that antidepressants might have had highly discrepant effects on cognitive measures and/or depressive symptoms.
Reports of adverse events like headache were based on spontaneous patient reports and were not assessed systematically, which might explain the small number of adverse events in our study in comparison with existing literature.
In unipolar depression, cognitive deficits are well established and encompass a wide range of deficits. Attention, short-term memory, psychomotor speed, 35 and executive functions 36 are the domains most affected. There is a growing body of evidence that bipolar patients in contrast to patients suffering from unipolar depression exert a different profile of cognitive deficits, 37, 38 even outlasting the acute phase of the disease. 39 In addition, chronically ill patients with bipolar disorder exhibit more severe cognitive impairments than those patients with a more remitting course of their illness. 40 Although we preferentially enrolled patients with unipolar depression (84.2%), our data might have been confounded by a differing cognitive output in both unipolar or bipolar depression.
CONCLUSIONS
Our results demonstrate that rTMS, conservatively spoken, had no negative impact on cognition in a 2-week trial. Actively treated groups even showed some improvement on several neuropsychological measures in the aftermath of the rTMS treatment. However, these improvements did not reach statistical significance in comparison with sham stimulation. Although the time × treatment data in memory could not withstand a Bonferroni correction, rTMS might have beneficial cognitive effects independent of its antidepressant efficacy.
The data extend prior findings as they indicate no detrimental effect on cognitive functioning in a stimulation paradigm using aggressive stimulation parameters outside current recommended guidelines and applied bilaterally to both frontal lobes. 
